Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 2/20 | 0.39 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.37 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.37 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2854435 | 0.85 | TSHR (0.48) | MAOBALDH1A1 | |
| SCHEMBL2856255 | 0.82 | GAA (0.48) | ALDH1A1 | |
| SCHEMBL2858150 | 0.81 | LMNA (0.52) | ALDH1A1 | |
| SCHEMBL2851648 | 0.80 | ALDH1A1 (0.51) | ALDH1A1 | |
| SCHEMBL2861180 | 0.79 | MMP13 (0.46) | ROCK2ALDH1A1 | |
| SCHEMBL2857253 | 0.77 | ALDH1A1 (0.47) | ALDH1A1 | |
| SCHEMBL20194473 | 0.76 | TRPV1 (0.47) | TRPV1MAOBPPARG | |
| SCHEMBL2852748 | 0.76 | GRM5 (0.40) | — | |
| SCHEMBL12784726 | 0.75 | TGM2 (0.58) | TRPV1MAOBPPARG | |
| SCHEMBL3168173 | 0.75 | CARM1 (0.46) | CARM1PRMT6ROCK2ROCK1TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140018549-A1 | USE OF D-SERINE DERIVATIVES FOR THE TREATMENT OF ANXIETY DISORDERS | NPS PHARMACEUTICALS, INC. (US) | 2014-01-16 | — | — | US | disclosed |
| US-7902401-B2 | Fluorinated compounds | NPS PHARMACEUTICALS, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| EP-1963277-B1 | FLUORINATED COMPOUNDS | NPS PHARMA INC (US) | 2010-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018549-A1 | USE OF D-SERINE DERIVATIVES FOR THE TREATMENT OF ANXIETY DISORDERS | OXSR1, SRR, GLRB | CARM1 2924/4885PRMT6 342/4885PDE10A 2891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.